These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 28973705)

  • 1. Identification and Management of
    Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
    South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next generation sequencing is informing phenotype: a TP53 example.
    O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ
    Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing.
    Rana HQ; Gelman R; LaDuca H; McFarland R; Dalton E; Thompson J; Speare V; Dolinsky JS; Chao EC; Garber JE
    J Natl Cancer Inst; 2018 Aug; 110(8):863-870. PubMed ID: 29529297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotype-phenotype associations among panel-based TP53+ subjects.
    Rana HQ; Clifford J; Hoang L; LaDuca H; Black MH; Li S; McGoldrick K; Speare V; Dolinsky JS; Gau CL; Garber JE
    Genet Med; 2019 Nov; 21(11):2478-2484. PubMed ID: 31105275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
    Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
    JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
    Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
    Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
    Fortuno C; James PA; Spurdle AB
    Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
    Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
    Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically.
    Coffee B; Cox HC; Bernhisel R; Manley S; Bowles K; Roa BB; Mancini-DiNardo D
    Hum Mutat; 2020 Jan; 41(1):203-211. PubMed ID: 31490007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients.
    Fortuno C; Pesaran T; Dolinsky J; Yussuf A; McGoldrick K; Kho PF; James PA; Spurdle AB
    Cancer Genet; 2019 Jun; 235-236():21-27. PubMed ID: 31296311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Terradas M; Mur P; Belhadj S; Woodward ER; Burghel GJ; Munoz-Torres PM; Quintana I; Navarro M; Brunet J; Lazaro C; Pineda M; Moreno V; Capella G; Evans DGR; Valle L
    Gut; 2021 Jun; 70(6):1139-1146. PubMed ID: 32998877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From uncertainty to pathogenicity: clinical and functional interrogation of a rare
    Quinn EA; Maciaszek JL; Pinto EM; Phillips AH; Berdy D; Khandwala M; Upadhyaya SA; Zambetti GP; Kriwacki RW; Ellison DW; Nichols KE; Kesserwan C
    Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 30886117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board.
    Xavier CB; Link R; Abreu L; Bettoni F; Marson F; Galante PAF; Masotti C; Amano MT; de Molla V; Camargo AA; Asprino PF; Sabbaga J
    Oncologist; 2023 Jul; 28(7):624-627. PubMed ID: 37159554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
    Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
    JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
    Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D
    Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Corrêa TS; Asprino PF; de Oliveira ESC; Leite ACR; Weis L; Achatz MI; de Oliveira CP; Sandoval RL; Barroso-Sousa R
    Genes (Basel); 2024 Jul; 15(7):. PubMed ID: 39062707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.
    Bakhuizen JJ; Hogervorst FB; Velthuizen ME; Ruijs MW; van Engelen K; van Os TA; Gille JJ; Collée M; van den Ouweland AM; van Asperen CJ; Kets CM; Mensenkamp AR; Leter EM; Blok MJ; de Jong MM; Ausems MG
    Fam Cancer; 2019 Apr; 18(2):273-280. PubMed ID: 30607672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.